Article in Infection and immunity, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors at 2 institutions in 1 country.
Mickael Vourc'hUniversité de Nantes, Thérapeutiques Cliniques et Expérimentales des Infections, EA 3826, Institut de Recherche en Santé 2 Nantes Biotech, Nantes, France.ORCID 0000-0002-1576-7728
Gaelle DavidEtablissement Français du Sang, Nantes, France.
Benjamin GaboritUniversité de Nantes, Thérapeutiques Cliniques et Expérimentales des Infections, EA 3826, Institut de Recherche en Santé 2 Nantes Biotech, Nantes, France.
Alexis BroquetUniversité de Nantes, Thérapeutiques Cliniques et Expérimentales des Infections, EA 3826, Institut de Recherche en Santé 2 Nantes Biotech, Nantes, France.ORCID 0000-0002-6635-9601
Cedric JacquelineUniversité de Nantes, Thérapeutiques Cliniques et Expérimentales des Infections, EA 3826, Institut de Recherche en Santé 2 Nantes Biotech, Nantes, France.ORCID 0000-0001-9606-5930
Tanguy ChaumetteUniversité de Nantes, Thérapeutiques Cliniques et Expérimentales des Infections, EA 3826, Institut de Recherche en Santé 2 Nantes Biotech, Nantes, France.ORCID 0000-0002-5830-8767
Jocelyne CaillonUniversité de Nantes, Thérapeutiques Cliniques et Expérimentales des Infections, EA 3826, Institut de Recherche en Santé 2 Nantes Biotech, Nantes, France.
Antoine RoquillyUniversité de Nantes, Thérapeutiques Cliniques et Expérimentales des Infections, EA 3826, Institut de Recherche en Santé 2 Nantes Biotech, Nantes, France.
Christelle RetiereEtablissement Français du Sang, Nantes, France.
Karim AsehnouneUniversité de Nantes, Thérapeutiques Cliniques et Expérimentales des Infections, EA 3826, Institut de Recherche en Santé 2 Nantes Biotech, Nantes, France karim.asehnoune@chu-nantes.fr.
Nantes Université · FRCentre National de la Recherche Scientifique · FR
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Natural killer (NK) cells play a key role in both antibacterial and antitumor immunity.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Pseudomonas aeruginosa Infection Impairs NKG2D-Dependent NK Cell Cytotoxicity through Regulatory T-Cell Activation. · full record | OpenQuestion